Fresh concerns have emerged about the platelet studies underpinning the FDA approval of ticagrelor, AstraZeneca's multibillion-dollar heart drug. A new BMJ investigation reveals data discrepancies, missing lab readings, and questions about the integrity of the trial process. Notably, key results reported in a major cardiology journal were inaccurately presented, and some study contributors were omitted or denied involvement. With generics on the horizon, critics say these revelations highlight potential dangers, including severe rebound effects and bleeding risks, that were never properly disclosed.
from Top Health News -- ScienceDaily https://ift.tt/TcNQGXv
No comments:
Post a Comment